SAN DIEGO and NEW YORK, Oct. 26 /PRNewswire/ -- SkinMedica, Inc. and New York University announced today that they have entered into a global license agreement to develop novel products to address skin hyperpigmentation based on technology invented at NYU.
Under the terms of the agreement, SkinMedica has licensed exclusive rights to develop and market products based on the NYU technology, with a range of applications in the modulation of skin pigmentation.
Hyperpigmentation is a common condition in which patches of skin become darker in color than the surrounding skin. It can affect the skin color of people of any race. Normal skin color is formed by melanin, which is produced by special cells called melanocytes in the top layer of the skin. Uneven melanin production can occur in response to hormonal changes, and may also occur with certain diseases. Another common presentation is in response to skin damage or inflammation. It is advisable for persons with pigmentary problems to visit a dermatologist for a discussion of diagnosis and treatment options, and to rule out skin cancer.
SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. We market and sell to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products.
SkinMedica's prescription products include VANIQA(R) (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the reduction of unwanted facial hair in women and EpiQuin(R) Micro Cream (4% hydroquinone) for hyperpigmentation, or "brown spots" that commonly result from aging, inflammation or sun exposure.
TNS Recovery Complex(R), VANIQA(R), EpiQuin(R) Micro, and SkinMedica(R), are registered trademarks of SkinMedica, Inc and affiliates.